secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-095749
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q2 net loss narrows to $5.9M; cash at $243M to fund Phase 3 in GAD
--------------------------------------------------------------------------

- Net loss of $5.9 million, down from $29.1 million in Q2 2023, primarily due to warrant fair value changes.
- Cash and equivalents of $243.1 million as of June 30, 2024; plus ~$70M net from July 2024 offering, extending runway into 2027.
- Completed end-of-Phase 2 meeting with FDA; first Phase 3 trial (Voyage) for MM120 ODT in GAD to start H2 2024 with topline in H1 2026.
- Expanding pipeline: registrational study (Emerge) for MM120 ODT in MDD planned for H1 2025, topline H2 2026.
- New USPTO patent issued covering MM120 ODT formulation and method of treatment, extending IP protection through 2041.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024095749/0000950170-24-095749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024095749/mnmd-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer